Glancy Binkow & Goldberg LLP Announces Investigation on Behalf of Shareholders of BioScrip, Inc.
28 Septembre 2013 - 5:32AM
Business Wire
Glancy Binkow & Goldberg LLP announces that it is
investigating potential claims on behalf of shareholders of
BioScrip, Inc. (“BioScrip” or the “Company”) (NASDAQ:BIOS)
concerning possible breaches of fiduciary duties by the Company or
its fiduciaries. The investigation is focused on certain statements
issued by the Company concerning BioScrip’s business and
operations.
Please contact us at 212-682-5340, Toll-Free at 888-773-9224, or
at shareholders@glancylaw.com to discuss this matter. If you
inquire by email please include your mailing address, telephone
number and number of shares purchased.
BioScrip provides home infusion, other home care services, and
pharmacy benefit management services in the United States. On
September 23, 2013, the Company disclosed that the United States
Attorney’s Office for the Southern District of New York and the New
York State Attorney General’s Medicaid Fraud Control Unit have
undertaken an investigation regarding the distribution of the
Novartis Pharmaceuticals Corporation product Exjade(R) by the
Company’s legacy specialty pharmacy division. The Company further
disclosed that it has provided documents and information to the
government regarding the distribution of Exjade, pursuant to a
civil investigative demand and a subpoena. Following this news, the
price of BioScrip shares declined more than 18%, to a closing price
of $8.47 per share on September 24, 2013.
If you purchased BioScrip shares and still hold those shares, if
you have information or would like to learn more about these
claims, or if you have any questions concerning this announcement
or your rights or interests with respect to these matters, please
contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg
LLP, 1925 Century Park East, Suite 2100, Los Angeles, California
90067, Toll-Free at 888-773-9224, or contact Gregory Linkh,
Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street,
Suite 2920, New York, New York 10168, at 212-682-5340, by e-mail to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email, please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los Angeles, CAMichael
Goldberg, 888-773-9224orGlancy Binkow & Goldberg LLP, New York,
NYGregory Linkh, 212-682-5340shareholders@glancylaw.comwww.glancylaw.com
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Août 2023 à Août 2024